Ibutilide fumarate is a new antiarrhythmic agent recently approved for the conversion of atrial flutter (AFl) and atrial fibrillation (AF) to normal sinus rhythm. A class III agent in the Vaughan Williams classification system, ibutilide prolongs cardiac repolarization by activating a slow inward,...
Chen C.L., Sangiah S., Berlin K.D., Scherlag B.J., Patterson E., Lazzara R. (1994): BRB-I-28: a novel class Ib antiarrhythmic agent. Cardiovasc. Drug Rev., 12, 237–253.C. L.Chen, S.Sangiah, K. D.Berlin, B.Scherlag, E.Patterson, R.Lazzara. (1994) BRB-I-28: A...
Ibutilide fumarate is a new antiarrhythmic agent recently approved for the conversion of atrial flutter (AFl) and atrial fibrillation (AF) to normal sinus rhythm. A class III agent in the Vaughan Williams classification system, ibutilide prolongs cardiac repolarization by activating a slow inward,...
6 Although a class Ia agent, it has an improved safety profile compared with quinidine; it does not induce QRS prolongation and is a less potent vagolytic agent than quinidine. Prolongation of the QT interval occurs following intravenous (i.v.) administration and may account for its proar...
The effects of bisaramil, a novel diazabicyclononane antiarrhythmic agent, were compared to those of lidocaine, a clinically used class Ib antiarrhythmic agent, on heart, skeletal muscle and brain Na+ channels expressed in Xenopus laevis oocytes using a two-electrode voltage clamp. Both bisara...
Morganroth J, Nestico PF, Horowitz LN. A review of the uses and limitations of tocainide — a Class IB antiarrhythmic agent. American Heart Journal 110: 856–863, 1985 ArticlePubMedCASGoogle Scholar Morganroth J, Orth DW, Michelson EL, et al. Comparative antiarrhythmic efficacy and tolerance...
Ibutilide: an arrhythmic agent for the treatment of atrial fibrillation or flutter. Ann Pharmacother 1999; 33: 38–47 Article PubMed CAS Google Scholar Anderson JL, Prystowsky EN. Sotalol: an important new antiarrhythmic. Am Heart J 1999; 137: 388–409 Article PubMed CAS Google Scholar ...
Conclusion: DC031050 is a highly selective hERG potassium channel blocker with a substantial safety margin of activity over neuronal potassium channels, thus holds significant potential for therapeutic application as a class III antiarrhythmic agent. Keywords: dofetilide; DC031050; class III ...
The resulting intermediate dihydropyridine compounds are reduced to 7 with a suitable reducing agent such as sodium borohydride in an inert solvent such as methanol or ethanol in a pH range of 2-4 at 0° C. to rt for 4-24 hours. An alternative synthesis of 7 can be accomplished by the ...
oral efficacy of ibutilide, a new class iii antiarrhythmic agent, in a conscious canine model of atrial flutterdoi:10.1016/0735-1097(91)91138-5L.V. BuchananU.M. TurcotteJ.K. GibsonG.G. KabellJournal of the American College of Cardiology...